Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases

Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders

Dr Sheela Nampoothiri appointed as co-chair of ICMR's Rare Diseases expert committee

Dr Ratna Puri from Sir Ganga Ram Hospital, Delhi is the Chairperson of the expert committee.

Elixirgen Therapeutics and Taisho Pharmaceutical tie-up to cure ageing-associated diseases

Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.

Alkem licenses technology from Harvard to treat ischemic injury and vascular diseases

Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy

Network18 Group and Novartis India launch ‘Netra Suraksha’ to raise awareness around diabetic eye diseases

The aim is to create an awareness programme that will drive diabetic patients to get their eyes tested regularly

Apollo Hospitals Seshadripuram expands cardiac care capacity with second Cath Lab

New facility equipped with advanced imaging technology to support 200 additional procedures a month and benefit nearly 3,000 more patients annually

Moderna reshapes leadership and ops model as it pushes into oncology, rare disease

CEO Stéphane Bancel framed the changes as essential to scaling the business

Can India become global clinical trials hub? Industry leaders to discuss road ahead on 19th June

Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination

Orionis expands Novartis partnership in potential $1.4 billion molecular glue drug feal

Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact

MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies